3 min read

UBC Receives Back-to-Back CRO Phase IV Leadership Award

UBC exceeded customer expectations in Phase IV clinical research, according to ISR’s CRO Quality Benchmarking annual online survey.
UBC received the CRO Leadership Award for Phase IV from Life Science Leader's survey of Pharma.

BLUE BELL, Pa., May 7, 2019 /PRNewswire/ — UBC, a global leader of late-stage and patient support services, for the second time in as many years, was named a leader in Phase IV clinical research, as a result of Industry Standard Research’s (ISR) Contract Research Organization (CRO) Quality Benchmarking annual online survey, in which more than 60 contract research organizations were evaluated, by global biopharmaceutical companies of all sizes, on more than 20 different performance metrics.

Life Science Leader Magazine’s Leadership Awards are based on sponsor ratings of work performed by CROs on recent outsourced projects. This experiential feedback is then analyzed, by sponsor company size, to reveal leading CROs in different performance categories. Some of the key metrics for the Leadership Award in Phase IV include:

  • Right first-time measurements
  • Strong regulatory track record
  • Track record for meeting quality performance metrics
  • Up-front contingency planning, risk management

In addition to achieving the above distinction for Phase IV work, UBC was also recognized for exceeding customer expectations in the area of meeting project timelines.

“UBC is pleased to receive this prestigious award. Our premier services in late stage development help pharmaceutical and biotech clients prove their products’ efficacy, safety, and value,” remarked Patrick Lindsay, President & CEO, UBC. “When it comes to the successful design and implementation of real-world, late phase studies, experience matters. We are fortunate to have team members with decades of scientific and global clinical operations expertise committed to our research sponsors and their patients.”

About UBC:

United BioSource LLC (UBC) is a leader in the biopharmaceutical market for integrated, comprehensive late stage and patient-support services. UBC brings together renowned scientific research and operations experts with leading-edge technologies, allowing for the best patient and healthcare provider experience. Comprehensive, end-to-end services cover product and patient population characterization during development and market entry, as well as focus on the patient experience, safety, and adherence. For additional information, visit the company’s website: www.ubc.com.

Other Recent Posts

3 min read

UBC Appoints Anthony Luttenberger Chief Commercial Officer

Biopharma services industry veteran brings decades of experience spanning late-stage, clinical trials, & post-approval commercial support.
1 min read

UBC Listed as a Citeline Awards Finalist for Excellence in RWE

UBC is once again a finalist for the Citeline Awards, with our 2024 nomination coming in the Excellence in RWE category.
3 min read

UBC Recognized as a Citeline Awards Finalist Again

The Citeline Awards have recognized UBC & Seqster’s innovative collaboration as a shortlisted finalist for the Best Patient-Facing Technology Initiative Category in 2023.

Thank You for Connecting with UBC

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

What You Can Expect Next

Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.

Get Ready to Change Your Business

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

Service Request

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.